

Dkt. 0575/61546-A-PCT/JPW/BJA
*DD 6A*IN THE INTERNATIONAL BUREAU OF WIPO

Applicant : THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK.

International Application No.: PCT/US01/26708

International Filing Date : August 28, 2001

For : DETECTION OF ANTI-GLYCOLIPID ANTIBODIES BY LATEX AGGLUTINATION ASSAY

1185 Avenue of the Americas
New York, New York 10036
February 25, 2002

International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Attn: Article 19 Amendment

AMENDMENT UNDER ARTICLE 19

This Amendment is submitted in accordance with Rule 46 to substitute original page 53 with replacement page 53 attached hereto as **Exhibit A**.

Claims 24-27 have been amended..

REMARKS

Applicants submits herewith replacement page 53 which has been amended to correct claims 24-27. Applicants maintain that replacement page 53 is submitted merely to correct the dependency of claims 24-27. The amended claims do not go beyond the disclosure in the international application as filed.

Applicant therefore respectfully request entry of replacement page 53.

Applicant : THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK.

International
Application No.: PCT/US01/26708


International
Filing Date : August 28, 2001
Page 2

A statement under PCT Article 19(1) is attached hereto as Exhibit B in accordance with Rule 46.4.

In accordance with PCT Rule 46.1, the time limit for filing an Amendment under Article 19 is two months from the date of transmittal of the international search report to the International Bureau and to the applicant by the International Searching Authority. The International Search Report was transmitted to the International Bureau on January 25, 2002. Therefore the deadline for filing an Amendment under Article 19 is March 25, 2002. Accordingly, this Amendment is being timely filed.

No fee is deemed necessary in connection with the filing of this Amendment.

Respectfully submitted,


John P. White
Registration No. 28,678
Attorney for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

directed against GM1.

23. The method of claim 21, wherein the antibody is directed against GD1a.

5

24. The method of claim 19, wherein the neuropathy is Guillain-Barré syndrome.

10 25. The method of claim 19, wherein the neuropathy is a Guillain-Barré syndrome variant.

26. The method of claim 19, wherein the neuropathy is a peripheral neuropathic disease.

15 27. The method of claim 19, wherein the neuropathy is a multifocal motor neuropathy.

28. A method of determining if a subject is predisposed to become afflicted with an autoimmune neuropathy, comprising quantitating the amount of an antibody directed against a ganglioside in the subject using the method of claim 7 or 8, wherein the presence of a predefined amount of the antibody indicates that the subject is predisposed to become afflicted with